Last reviewed · How we verify
Glycemic Rescue 1
Glycemic Rescue 1 is designed to rapidly restore blood glucose control in acute hyperglycemic states.
Glycemic Rescue 1 is designed to rapidly restore blood glucose control in acute hyperglycemic states. Used for Acute hyperglycemia or glycemic rescue in diabetes.
At a glance
| Generic name | Glycemic Rescue 1 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
The drug appears to target acute glycemic dysregulation through an undisclosed mechanism. Given the name and phase 3 status, it likely acts through insulin secretion enhancement, glucose utilization improvement, or hepatic glucose production inhibition. The specific molecular target and detailed mechanism are not publicly available.
Approved indications
- Acute hyperglycemia or glycemic rescue in diabetes
Common side effects
Key clinical trials
- Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083) (PHASE3)
- A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289) (PHASE3)
- Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly (PHASE4)
- Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002) (PHASE3)
- A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848) (PHASE3)
- A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001) (PHASE1)
- Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017) (PHASE3)
- Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glycemic Rescue 1 CI brief — competitive landscape report
- Glycemic Rescue 1 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI